The 13-valent pneumococcal conjugate vaccine reduced nearly by half vaccine-type community acquired pneumonia in adults aged 65 years and older.
Tezepelumab Found to Reduce Rate of COPD Exacerbations in Persons with Wide Range of Blood Eosinophil Levels: Daily Dose
Your daily dose of the clinical news you may have missed.
Respiratory Tripledemic 2022-23: An Expert Recap
William Schaffner, MD, medical director of the NFID, provides an expert recap of the 2022-2023 respiratory virus season for primary care clinicians.
Dupilumab in Replicate Phase 3 Trial Significantly Reduces COPD Exacerbations, Improves Lung Function, with PDUFA Date in Sight
Dupilumab reduced COPD exacerbations by 34% in adults with uncontrolled symptoms and evidence of T2 inflammation, and significantly improved lung function.
NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half
In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.
Moderna Will Have to Wait for FDA Approval of Investigational RSV Vaccine
While Moderna expects mRNA-1345 to be approved later this month, the company cites FDA administrative constraints as reason for delay.
Budesonide-Based Triple Therapy Most Cost-Effective vs Dual Therapy for COPD
A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.